Cargando…

Improving target cell specificity using a novel monovalent bispecific IgG design

Monovalent bispecific IgGs cater to a distinct set of mechanisms of action but are difficult to engineer and manufacture because of complexities associated with correct heavy and light chain pairing. We have created a novel design, “DuetMab,” for efficient production of these molecules. The platform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazor, Yariv, Oganesyan, Vaheh, Yang, Chunning, Hansen, Anna, Wang, Jihong, Liu, Hongji, Sachsenmeier, Kris, Carlson, Marcia, Gadre, Dhanesh V, Borrok, Martin Jack, Yu, Xiang-Qing, Dall’Acqua, William, Wu, Herren, Chowdhury, Partha Sarathi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622537/ https://www.ncbi.nlm.nih.gov/pubmed/25621507 http://dx.doi.org/10.1080/19420862.2015.1007816

Ejemplares similares

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017)

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance
por: Shan, Lu, et al.
Publicado: (2021)

Insights into the molecular basis of a bispecific antibody's target selectivity
por: Mazor, Yariv, et al.
Publicado: (2015)

Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen
por: Mazor, Yariv, et al.
Publicado: (2016)

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
por: Wang, Bo, et al.
Publicado: (2019)

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
por: Bagert, John D., et al.
Publicado: (2023)

Structural characterization of a human Fc fragment engineered for lack of effector functions
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon α-2A
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format
por: Xiao, Xiaodong, et al.
Publicado: (2015)

Generation and Characterization of an IgG4 Monomeric Fc Platform
por: Shan, Lu, et al.
Publicado: (2016)

Mechanisms of Neutralization of a Human Anti-α-toxin Antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2014)

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
por: Geoghegan, James C., et al.
Publicado: (2016)

A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture
por: Wang, Chunlei, et al.
Publicado: (2018)

Long-acting antibody ligand mimetics for HER4-selective agonism
por: Shan, Lu, et al.
Publicado: (2020)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

The application of mathematical modelling to the design of bispecific monoclonal antibodies
por: van Steeg, Tamara J., et al.
Publicado: (2016)

Fab-Arm Exchange Combined with Selective Protein A Purification Results in a Platform for Rapid Preparation of Monovalent Bispecific Antibodies Directly from Culture Media
por: Steinhardt, James, et al.
Publicado: (2019)

Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays
por: Peng, Li, et al.
Publicado: (2014)

Effect of monovalency on anti-contactin-1 IgG4
por: Taieb, Guillaume, et al.
Publicado: (2023)

Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
por: Allen, Kevin L., et al.
Publicado: (2020)

Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
por: Allen, Kevin L., et al.
Publicado: (2021)

The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
por: Peng, Li, et al.
Publicado: (2012)

Characterization and analysis of scFv-IgG bispecific antibody size variants
por: Cao, Mingyan, et al.
Publicado: (2018)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

BEAT(® )the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs
por: Moretti, Pierre, et al.
Publicado: (2013)

Divalent ligand-monovalent molecule binding
por: Janssen, Mathijs, et al.
Publicado: (2021)

Engineering IgG-Like Bispecific Antibodies—An Overview
por: Krah, Simon, et al.
Publicado: (2018)

Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers
por: Walseng, Even, et al.
Publicado: (2023)

Tethered-variable C(L) bispecific IgG: an antibody platform for rapid bispecific antibody screening
por: Kim, Hok Seon, et al.
Publicado: (2017)

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
por: Harwood, Seandean Lykke, et al.
Publicado: (2017)

Influence of the bispecific antibody IgG subclass on T cell redirection
por: Kapelski, Stephanie, et al.
Publicado: (2019)

Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region
por: Handlogten, Michael W., et al.
Publicado: (2020)

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis
por: Fichtner, Miriam L., et al.
Publicado: (2020)

Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific
por: Ramasubramanian, Anusuya, et al.
Publicado: (2020)

Molecular basis for the mechanism of action of an anti-TACE antibody
por: Peng, Li, et al.
Publicado: (2016)

We need to bring R0 < 1 to treat cancer too
por: Srikrishna, Devabhaktuni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_prcslbbb7uicfc9gs0g68neaaj